Recommended Free Tools
A 2017 Merck study reported a metal-free catalyst that helps chemists control the configuration of phosphorus when attaching phosphoramidate groups to nucleosides. The method reached stereoselectivity as high as 99:1 in the study, offering a catalytic alternative to approaches based on separating stereoisomers or using stoichiometric chiral auxiliaries.
Why phosphorus chirality matters in ProTide synthesis
ProTides are pronucleotide prodrugs: they attach a phosphoramidate group to a nucleoside to help deliver a nucleotide-like molecule. In some of these compounds, the phosphorus atom is stereogenic, meaning its arrangement can take different configurations. Those configurations are distinct stereoisomers, and controlling which one forms is a central synthetic challenge.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Organic Chemistry | $125.24 | Buy on Amazon |
| 2 |
|
Organic Chemistry (MasteringChemistry) | $319.99 | Buy on Amazon |
| 3 |
|
Organic Chemistry as a Second Language: First Semester Topics | $76.48 | Buy on Amazon |
| 4 |
|
Organic Chemistry | $65.32 | Buy on Amazon |
| 5 |
|
Organic Chemistry I For Dummies (For Dummies (Math & Science)) | $11.48 | Buy on Amazon |
As an Amazon Associate I earn from qualifying purchases.
Before the catalyst described in 2017, established ways to address this challenge included making stereoisomers and separating them, or relying on stoichiometric chiral auxiliaries. Separation can add a difficult step, while an auxiliary is used in stoichiometric rather than catalytic amounts. The Merck team presented its work as a way to achieve stereocontrol catalytically instead.
How the reported catalyst works
Daniel A. DiRocco and coauthors described a dynamic stereoselective process for installing phosphorus-stereogenic phosphoramidates onto nucleosides. Their multifunctional catalyst was designed following detailed mechanistic studies and computational modeling. The primary abstract reports selectivity as high as 99:1; that is the study’s maximum reported result, not a guarantee for every substrate or reaction.
#1 Best Overall
The significance is specific: the catalyst system addresses stereoselective phosphoramidation of nucleosides. The study does not establish a general method for controlling chirality in every phosphorus-containing molecule, nor does it show that the same catalyst can be used unchanged with all nucleosides. The PubMed record and abstract summarize the paper’s claims and publication details.
How the strategy compares with earlier approaches
| Approach | What it does | What the 2017 sources establish |
|---|---|---|
| Catalytic stereoselective synthesis | Uses a catalyst to favor formation of a phosphorus stereoisomer during phosphoramidation. | The DiRocco study reports a multifunctional, metal-free catalyst and selectivity as high as 99:1; it does not provide a universal performance figure for other substrates. |
| Resolution | Separates stereoisomers after they have formed. | The authors identify resolution as an established prior approach; the cited sources do not give a directly comparable numerical performance measure. |
| Stoichiometric chiral auxiliaries | Uses a chiral auxiliary in stoichiometric quantity to influence stereochemical outcome. | The authors identify this as another established prior approach; the cited sources do not give a directly comparable numerical performance measure. |
The comparison is about the synthetic logic, not a head-to-head performance ranking. The study’s reported selectivity supports the catalyst’s promise in its demonstrated context, but the available sources do not establish comparative catalyst loading or a numerical advantage across a broad range of substrates.
Rank #2
What the examples show—and what they do not
The paper describes work on MK-3682, a hepatitis C candidate, and reports that its selectivity principles applied to other nucleoside analogs, including an AZT derivative. These examples illustrate the method’s application and scope as reported in 2017. They do not establish the present clinical status of MK-3682 or current commercial availability of any product.
Free tools Windows power users keep installed
One-click scans. No signup required.
The full-text issue pages from Science cover the article and its examples. A contemporary Chemistry World report described MK-3682 as being in Phase 3 trials at the time of publication in April 2017; that is a dated report, not a current trial update.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What the result means for drug chemistry
The advance was a demonstration that a designed catalyst could guide stereochemistry at phosphorus during a relevant nucleoside phosphoramidation, rather than treating the phosphorus center as a stereochemical problem to solve only through resolution or a stoichiometric auxiliary. Its reported maximum selectivity of 99:1 makes the result notable, while the reaction context and examples define the limits of what can be concluded from the paper.
Quick Recap
Best Value
Rank #4
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
